Gilead fights back to make exclusive deal with CVS
2015/1/11 E药经理人

     Gilead Sciences' hepatitis C drugs, Sovaldi and Harvoni, will get exclusive coverage on several plans from CVS, the pharmacy benefits manager said on Jan 5, taking the opposite stance from competitor Express Scripts. Last month, shares of Gilead swooned after Express Scripts said it would exclusively offer competitor AbbVie's newly approved hepatitis C therapy Viekira Pak on its largest plan.

     The deal was effective on January 7, 2015. "Our goal was to create the lowest net-cost solution for the entire population of patients with all genotypes of hepatitis C," CVS' Cramer said in the statement. At USD 84,000 for 12 weeks of treatment, Sovaldi set off a storm of controversy when it was approved in December 2013. Harvoni, a combination of Sovaldi and ledipasvir, was approved in October; it costs USD 94,500 for 12 weeks of treatment, though some patients are cured in just eight weeks.

    http://www.duyihua.cn
返回 E药经理人 返回首页 返回百拇医药